One preclinical data has demonstrated that targeted sgPLK1-cLNPs significantly enhance survival rates, achieving an 80% improvement in ovarian tumor mice models.265 The other two target PLK1 in A375 tumor-bearing mice266 and HepG2 tumor bearing mice267 didn’t show sufficient response. This evidence concerns the gene PLK1 and neoplasm.